

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 30436.43USU1		Application Number: 08/905,293	
	Applicant: Dale E. Yelton and Mae Joanne Rosok			
	Filing Date: August 1, 1997		Group Art Unit: <del>1945</del> 1641	
	FEB 02 1998			

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
2/95	EP 0 699 756 A1	3/6/96	EPO (Exhibit 1)				
2/95	WO 94/29351	12/22/94	PCT (Exhibit 2)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
2/95		D. Yelton, et al., "Mutant Monoclonal Antibodies With Alterations in Biological Functions," <u>J. Exp. Medicine</u> , Vol. 56, pp. 1131-1148, October 1982 (Exhibit 3)
		Mueller, et al., "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the C <sub>H</sub> 2 Domain and Directed Against the Disialoganglioside GD2," <u>P.N.A.S.</u> , Vol. 87, pp. 5702-5705, August 1990 (Exhibit 4)
		H. Garrigues, et al., "Detection of a Human Melanoma-Associated Antigen, p97, in Histological Sections of Primary Human Melanomas," <u>Int. J. Cancer</u> , Vol. 29, pp. 511-515, 1982 (Exhibit 5)
		Alexander R. Duncan, et al., "The Binding Site for Clq on IgG" <u>Nature</u> , Vol. 332, pp. 738-740, April 1988 (Exhibit 6)
		Mi-Hua Tao, et al., "Structural Features of Human Immunoglobulin G That Determine Isotype-Specific Differences in Complement Activation" <u>J. Exp. Med.</u> , Vol. 178, No. 2, pp. 661-667, August 1993 (Exhibit 7)
		Yuanyuan. Xu, et al., "Residue at Position 331 in the IgG1 and IgG4 Domains Contributes to Their Differential Ability to Bind and Activate Complement" <u>J. Biol. Chem.</u> , Vol. 269, No. 5, pp. 3469-3474, February 1994 (Exhibit 8)
		A. Morgan, et al., "The N-Terminal End of the C <sub>H</sub> 2 Domain of Chimeric Human IgG1 Anti-HLA-DR is Necessary for Clq, FcγRI and FcγRIII Binding" <u>Immunology</u> , Vol. 86, pp. 319-324, 1995 (Exhibit 9)
		Mae Joanne Rosok, et al. "A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab," <u>J. Biol. Chem.</u> , Vol. 271, No. 37, pp. 22611-22618, September 1996 (Exhibit 10)
2/95		Mi-Hua Tao, et al., "The Differential Ability of Human IgG1 and IgG4 to Activate Complement is Determined by the COOH-Terminal Sequence of the C <sub>H</sub> 2 Domain," <u>J. Exp. Med.</u> , Vol. 173, pp. 1025-1028, April 1991 (Exhibit 11)

EXAMINER	2/95	DATE CONSIDERED	01 Feb. 99
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

Date Mailed: January 29, 1998

Sheet 2 of 2

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 30436.43USU1		Application Number: 08/905,293
	Applicant: Dale E. Yelton and Mae Joanne Rosok		
	Filing Date: August 1, 1997		Group Art Unit: <del>1848</del> 1641

<i>2us</i>	I. Hellström, et al., "Strong Antitumor Activities of IgG3 Antibodies to a Human Melanoma-Associated Ganglioside," P.N.A.S., Vol. 82, pp. 1499-1502, March 1985 (Exhibit 12)
------------	--

EXAMINER <i>2us</i>	DATE CONSIDERED 01 Feb. 99
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

